Every 8-K that TEVOGEN INC (TVGN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow TVGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TVGN filings page.
Tevogen Inc. (TVGN) stated that on September 9, 2026 it received written notice from Nasdaq that it has regained compliance with the $15 million minimum market value of publicly held shares requirement under Nasdaq Listing Rule 5450(b)(2&3)(C) for continued listing on the Nasdaq Global Market. Nasdaq informed the company that the compliance matter is now closed.
Tevogen Inc. (TVGN) reported results of its August 24, 2026 annual stockholder meeting and related governance changes. Stockholders approved an amendment to the Tevogen Inc. 2024 Omnibus Incentive Plan, increasing the shares of common stock available for issuance under the plan by 100,000,000.
Stockholders also approved a Certificate of Amendment to the Certificate of Incorporation, filed on August 26, 2026, to permit stockholders to act by written consent in lieu of a meeting, effective upon filing. As of the July 23, 2026 record date, there were 6,416,540 shares outstanding, with 5,956,141 shares represented at the meeting, constituting a quorum. Two Class II directors were elected and KPMG LLP was ratified as independent auditor for 2026.
Tevogen Bio Holdings Inc., a Delaware corporation, has amended its Certificate of Incorporation to change its name to Tevogen Inc. A Certificate of Amendment was filed on July 29, 2026, and the name change became effective on July 30, 2026. The board also approved a conforming amendment to the Amended and Restated Bylaws, with no other bylaw changes.
The company’s common stock, par value $0.001 per share, and public warrants, exercisable at $575 per share, continue to trade on the Nasdaq Global Market under their existing ticker symbols. The CUSIP numbers 88165K200 for common stock and 88165K119 for warrants are unchanged, and the name change does not affect the rights of security holders.
Tevogen Bio Holdings Inc. has been notified by Nasdaq that it no longer meets two key Nasdaq Global Market listing standards tied to market value. Nasdaq found the company was below the $50 million minimum market value of listed securities and the $15 million minimum market value of publicly held shares for 30 consecutive business days. The stock remains listed for now, and Tevogen has 180 days, until October 13–14, 2026, to regain compliance by maintaining required market values for at least 10 consecutive business days. The company will monitor its market value and may consider actions, including a potential transfer to the Nasdaq Capital Market, but it cannot assure it will regain or maintain compliance.
Tevogen Bio Holdings Inc. is implementing a 1-for-50 reverse stock split of its common stock, effective March 6, 2026. The move is intended to help the company regain compliance with Nasdaq’s $1.00 minimum bid price requirement for continued listing on the Nasdaq Global Market.
As of March 3, 2026, the company had 202,416,556 shares of common stock issued and outstanding, which will be consolidated at the 50-to-1 ratio. Authorized common shares will remain at 800,000,000. No fractional shares will be issued; instead, holders entitled to a fraction will receive cash based on the closing price before the split.
The common stock will begin trading on a split-adjusted basis on March 6, 2026 under the same symbol, TVGN, with a new CUSIP number 88165K200. Outstanding preferred stock, warrants, equity awards, and plan share reserves will be adjusted proportionally, and the reverse split is designed to affect all stockholders uniformly, aside from minor changes from fractional share cash-out.
Tevogen Bio Holdings Inc. reported that stockholders approved two key proposals at a special meeting. First, they approved an amendment to the 2024 Omnibus Incentive Plan, adding 100,000,000 shares of common stock available for equity awards, which can be adjusted if a future reverse stock split occurs.
Stockholders also approved an amendment to the Certificate of Incorporation authorizing a reverse stock split of issued and outstanding common shares at a ratio between 1:25 and 1:85, with the exact ratio and timing left to the Board’s discretion, if implemented. At the record date, 201,522,282 shares were outstanding, and 182,412,517 shares were represented at the meeting. Both proposals received strong support based on the reported vote tallies.
Tevogen Bio Holdings Inc. reported that its Board of Directors has expressed an intention to evaluate the potential declaration of a one-time special cash dividend for shareholders. Any dividend would follow the satisfaction of financial milestones that will be determined at a future date.
The update was shared through a press release issued on January 30, 2026 and furnished under a Regulation FD disclosure, signaling an early-stage, exploratory step rather than a finalized dividend decision.
Tevogen Bio Holdings Inc. reported that it received a notice from Nasdaq on September 23, 2025 stating that its common stock no longer meets the Nasdaq Global Market’s $1.00 per share minimum bid price requirement under Listing Rule 5450(a)(1). This determination was based on the stock’s closing bid price over the previous 30 consecutive business days, but the notice does not immediately affect the stock’s listing or trading status.
The company has 180 calendar days, until March 23, 2026, to regain compliance. It will be considered back in compliance if the closing bid price is at least $1.00 per share for a minimum of 10 consecutive business days and generally not more than 20 consecutive business days. If compliance is not restored by that date, Tevogen may seek an additional 180-day period by transferring to the Nasdaq Capital Market and meeting that market’s other initial listing standards.
Tevogen states that it will monitor the closing bid price and the market integrity of its common stock and may evaluate options to regain compliance, but it cautions that there is no assurance it will take any specific action or succeed in maintaining compliance with Nasdaq’s listing rules.